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Background: The CURRENT/OASIS 7 study showed that doubling dose of clopidogrel for 7 days in high-risk patients can reduce the risk of major 
adverse cardiovascular events. Because East Asian population has a higher prevalence of cytochrome (CYP) 2C19 polymorphism than Caucasian 
(60% vs. ~30%), it is important to warrant whether high maintenance-dose clopidogrel of 150 mg/d (HMDC) can overcome the loss-of-function 
effect of genetic polymorphism.
Methods: We enrolled 126 high-risk patients recieving HMDC after PCI (≥ 1 mo). Platelet reactivity (PR) was assessed by conventional 
aggregometry and the VerifyNow P2Y12 assay. High post-treatment platelet reactivity (HPPR) was defined as 5 uM ADP-induced maximal platelet 
reactivity (PRmax) ≥ 50%. CYP2C19, CYP2B6, CYP3A5, and ABCB1 polymorphisms were evaluated.
Results: Compared with the non-carriers, the carriers of CYP2C19*2 or *3 mutant allele showed higher PRmax after 5 uΜ and 20 uM ADP stimuli 
(40.7 ± 16.8% vs. 30.3 ± 12.6%, p < 0.001 and 54.2 ± 16.2% vs. 40.5 ± 15.8%, p < 0.001, respectively). Likewise, late PR and P2Y12 reaction unit 
were also greater in the carriers of CYP2C19 variant than the non-carriers. However, carriage of CYP2B6*5, CYP3A5*3 and ABCB1 polymorphisms 
were not associated with reduced platelet inhibition with HMDC. The prevalence of HPPR on HMDC was 21.4% , and the carriers of CYP2C19 variant 
demonstrated higher rate of HPPR than the non-carriers (8.7% vs. 28.8%, p = 0.012). In multivariate analysis (age, sex, BMI, genetic polymorphism, 
previous myocardial infarction or stroke, smoking status, hypertension, diabetes, chronic kidney disease, left ventricular ejection fraction ≤ 45%, 
administration of beta blocker, ACE inhibitor, angiotensin receptor blocker, calcium channel blocker or proton pump inhbitor), carriage of CYP2C19 
mutant allele was only an independent predictor of HPPR (odds ratio 5.405, 95% confidence interval 1.333 to 22.222, p = 0.018).
Conclusions: Doubling maintenance-dose clopidogrel can not overcome the loss-of-function effect of CYP2C19 polymorphism.
